Intuitive Surgical, Inc. — Medical Instruments & Supplies. Scored on the same transparent 7-signal model behind the daily rankings.
★
ISRG
Intuitive Surgical, Inc. · Medical Instruments & Supplies
FCF$2.8bB
Rev+20.5%A-
D/E——
P/E49.7xC
PEG2.26C
72.1Score
$409.05$144.9B
1Y Target$563.35Analyst consensus · 29 analysts
5Y Target$824.81Compound horizon
10Y Target$1,224Long-dated conviction
FCF$2.8bTTMB
FCF $2.8b — solid, comfortably covers operations and capital return
Rev+20.5%TTM YoYA-
Revenue +20.5% — strong growth, well above S&P median (~7%)
D/E——
D/E data unavailable — neutral default
P/E49.7xC
P/E 49.7 — expensive vs Healthcare peers (≈90th pctile)
PEG2.26C
PEG 2.26 — expensive relative to growth rate
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 72.1
Quality0.83
Growth0.99
Value0.46
Entry · Margin of safety
52-week rangeNear 52-week low
32% off the 12-month high
vs DCF fair value280% aboveest. fair value ~$108
Quality signals · context only
Gross profitability35% · B+gross profit ÷ total assets (Novy-Marx)
ROIC14.6% · B+return on invested capital — not score-weighted
Why now
Medical Instruments & Supplies · market cap $144.9b. Down 32% from 52-week high of $603.88 — deep drawdown territory. Revenue growing +21%, comfortably above the S&P median. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $563.35 (implying +38% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 50x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon
1-3 yr $563.35 (29-analyst consensus) — fundamentals + valuation re-rating. 5 yr $824.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,224 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · ISRG
Trend
+0.5 over 14 daily scores
From 71.6 (Jun 22) → 72.1 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · ISRG
$
%
%
Shares to buy
4
Position size
$1,636
3.3% of portfolio
Stop price
$306.79
25% below $409.05
$ at risk if stopped
$409.05
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Intuitive Surgical, Inc. (ISRG): score, valuation & FAQ
Intuitive Surgical, Inc. (ISRG) is a Medical Instruments & Supplies company that scores 72.1 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-). On valuation, ISRG sits about 280% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is ISRG a good stock to buy?
Bull Rankings scores ISRG 72.1 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A-). A score is a quantitative screen of Intuitive Surgical, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ISRG score 72.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ISRG earns its highest marks on Rev (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ISRG overvalued or undervalued?
Based on $409.05, ISRG sits about 280% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 49.7x× P/E (graded C). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ISRG?
Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 50x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.